Quantcast

Latest Estrogens Stories

2014-10-16 08:32:16

NORTHRIDGE, Calif., Oct. 16, 2014 /PRNewswire/ -- Post-menopausal women experienced improvements in vaginal atrophy, with no significant effect on hormone levels or genital bleeding, after 12 weeks of daily 10 milligram (mg) doses of an investigational fermented soy germ-based nutritional supplement previously shown to help relieve certain menopause symptoms, according to a new peer-reviewed pilot study reported in a poster at the North American Menopause Society (NAMS) annual...

2014-10-16 08:31:02

~The DiVA Circle is Challenging Canadian Women to Talk Openly About VA, Encouraging them to Elevate the Dialogue~ TORONTO, Oct. 16, 2014 /CNW/ - The Dedicated Influencers on Vaginal Atrophy (DiVA) Circle is calling for Canadian women to once and for all break the taboo of discussing vaginal atrophy (VA), a chronic and common condition of menopause. The time to discuss VA is now. VA, which is caused by estrogen deficiency, affects approximately 45 per cent of postmenopausal women(1)...

2014-10-01 08:33:14

FLORHAM PARK, N.J., Oct. 1, 2014 /PRNewswire/ -- Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from clinical trials of ospemifene (available in the U.S. marketplace as Osphena(®)) at the 25(th) Annual Meeting of The North American Menopause Society (NAMS) in Washington, DC on October 15-18, 2014. Osphena(®) (ospemifene) is approved for the treatment of moderate to severe dyspareunia, a symptom of...

2014-09-24 12:30:16

Minivelle now approved for prevention of postmenopausal osteoporosis at all doses MIAMI and NEW YORK, Sept. 24, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to...

2014-08-21 12:30:21

DUBLIN, Ireland, August 21, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" [http://www.researchandmarkets.com/research/3zh3q8/global_hormone ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Hormone replacement therapy, also known as hormone therapy, is a means of replacing...

2014-08-05 23:06:47

JDS Therapeutics Announces U.S. Launch of Physician Recommended Relizen®, a Safe, Natural Therapy for Hot Flashes Los Angeles (PRWEB) August 05, 2014 Relizen®†, a patented, non-hormonal nutritional supplement for the relief of hot flashes associated with menopause, is now available to U.S. consumers for purchase at Relizen.com. Over 43 million women are of menopausal age in the United States. Seventy-five percent of women report experiencing hot flashes, and 87 percent of...

2014-07-15 16:25:16

NEW YORK, July 15, 2014 /PRNewswire/ -- According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018. Due to a variety of factors, such as an aging worldwide population, an increasing awareness among patients and physicians, the introduction of new therapies into the market, and the overall disease pattern and treatment differences between men and women, this market is expected to grow at a CAGR of 3.5% over the next five...

2014-06-18 12:34:08

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Hormone Replacement Therapy (HRT) Industryhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/hormone_replacement_therapy_hrt.html This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and...

2014-05-29 20:22:54

New offering through an agreement with Meda AB expands Mission's women's healthcare options SAN ANTONIO, May 29, 2014 /PRNewswire/ -- Mission Pharmacal Company has begun exclusive promotion of Elestrin® (estradiol gel) 0.06% in the United States through an agreement with Meda AB. Elestrin is a prescription medicine approved by the Food and Drug Administration (FDA) for use as a topical hormone replacement gel to treat moderate-to-severe hot flashes due to menopause. Using estrogen-alone may...

2014-04-04 08:25:40

NORTHRIDGE, Calif., April 4, 2014 /PRNewswire-USNewswire/ -- A daily dose of S-equol (13.1 mg), delivered via a fermented soy germ-based nutritional supplement to manage menopause symptoms, showed no impact on reproductive or thyroid hormones or the menstrual cycles of premenopausal women, according to a peer-reviewed study reported in a poster at the Academy of Women's Health 2014 annual meeting in Washington, DC. Previous controlled clinical trials documented that daily doses of...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related